OR WAIT 15 SECS
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch.
Liz Barrett, CEO, UroGen Pharma: A Speciality Calling in Cancer
Click here to read the articles and download the PDF
Highlighted Videos
October 20, 2020
The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.
October 18, 2020
This week's much-anticipated meeting of FDA’s vaccine advisory committee will address critical issues related to the testing and approval of vaccines to prevent COVID-19 infection.
October 15, 2020
Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.
Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.
Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.
Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.
October 14, 2020
When the people are the sole assets.
How ramped-up support and educational services have helped bridge the chasms and ease fears along the patient care continuum.
Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
Missteps threaten agency’s independence as vaccines seek finish line.
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Tips for rounding out the rough edges in crossover.
The role of advanced data technologies in reducing hurdles.
Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch
Previewing executive trends thought of by leaders in the pharma industry.
Universal strategy push elicits range of constituency views.
Biopharma must find sustainable models for public policy engagement.
October 13, 2020
Michael Wong speaks to Frank Cespedes, a senior lecturer at Harvard Business School, about how biopharma companies should be optimizing their sales and engagement activities for the 2020s.
Female medical affairs leaders speak out with unique perspectives on how MSLs can provide greater value to opinion leaders.
October 09, 2020
Ashfield and IPCAA join forces to find out what HCPs really think about virtual medical congresses in new global study.
October 08, 2020
FDA has published updated Emergency Use Authorization (EUA) requirements for new coronavirus preventives.
October 07, 2020
In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Percival Barretto-Ko, President of Astellas Pharma, US, speaks to Michael Wong about why value and innovation are the top two focus areas to add to resumes in 2020.
October 06, 2020
AI-powered platform can transform medical expert and opinion leader engagement planning for medical affairs teams.
Pharmaceutical R&D industry report provides insights into what’s behind decline in global NME outputs and reveals implications of decreased projected expenditures.
While gene therapies continue to revolutionize healthcare, uncertainty from commercialization issues still looms large.
October 05, 2020
Experts fear confusion over allocation process, cold-chain requirements, IT systems.
October 01, 2020
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
September 30, 2020
Fiona Huzarski outlines four key recruitment lessons that pharma can take from the coronavirus crisis and use to move forward and thrive.
